Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice

被引：15

作者：

Yamada, Yutaka ^{[1
]}

Tamura, Tomohiro ^{[1
]}

Yamamoto, Yusuke ^{[2
,3
]}

Ichimura, Hideo ^{[2
,3
]}

Hayashihara, Kenji ^{[4
]}

Saito, Takefumi ^{[4
]}

Yamada, Hideyasu ^{[5
]}

Endo, Takeo ^{[6
,7
]}

Nakamura, Ryota ^{[6
,7
]}

Inage, Yoshihisa ^{[6
,7
]}

Satoh, Hiroaki ^{[8
,9
]}

Iguchi, Kesato ^{[8
,9
]}

Saito, Kazuto ^{[10
,11
]}

Inagaki, Masaharu ^{[10
,11
]}

Kikuchi, Norihiro ^{[12
]}

Kurishima, Koichi ^{[13
,14
]}

Ishikawa, Hiroichi ^{[13
,14
]}

Sakai, Mitsuaki ^{[13
,14
]}

Kamiyama, Koichi ^{[15
]}

Shiozawa, Toshihiro ^{[16
]}

Hizawa, Nobuyuki ^{[16
]}

Sekine, Ikuo ^{[16
]}

Sato, Yukio ^{[16
]}

Funayama, Yasunori ^{[17
]}

Miyazaki, Kunihiko ^{[18
]}

Kodama, Takahide ^{[18
]}

Hayashi, Shigen ^{[19
]}

Nomura, Akihiro ^{[19
]}

Nakamura, Hiroyuki ^{[20
]}

Furukawa, Kinya ^{[20
]}

Yamashita, Takaaki ^{[21
]}

Okubo, Hatsumi ^{[1
]}

Suzuki, Hisashi ^{[1
]}

Kiyoshima, Moriyuki ^{[1
]}

Kaburagi, Takayuki ^{[1
]}

机构：

[1] Ibaraki Prefectural Cent Hosp & Canc Ctr, Resp Ctr, 6528 Koibuchi, Kasama, Ibaraki 3091793, Japan

[2] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan

[3] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan

[4] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan

[5] Univ Tsukuba, Hitachinaka Gen Hosp, Div Resp Med, Hitachinaka Med Ctr, Hitachinaka, Ibaraki, Japan

[6] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[7] Mito Med Ctr, Div Thorac Surg, Mito, Ibaraki, Japan

[8] Univ Tsukuba, Mito Kyodo Gen Hosp, Div Resp Med, Mito Med Ctr, Mito, Ibaraki, Japan

[9] Univ Tsukuba, Mito Kyodo Gen Hosp, Div Thorac Surg, Mito Med Ctr, Mito, Ibaraki, Japan

[10] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[11] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan

[12] Kasumigaura Med Ctr Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[13] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[14] Tsukuba Med Ctr Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[15] Tsukuba Mem Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[16] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan

[17] Tsukuba Gakuen Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[18] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan

[19] Ibaraki Seinan Med Ctr Hosp, Div Resp Med, Sakai, Osaka, Japan

[20] Tokyo Med Univ, Ibaraki Med Ctr, Div Resp Med, Ami, Japan

[21] JA Toride Med Ctr Hosp, Div Resp Med, Toride, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 10期

关键词：

Clinical practice; non-small cell lung cancer; uncommon mutation; EGFR; epidermal growth factor receptor; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; AFATINIB; GEFITINIB; EFFICACY; TKI;

D O I：

10.21873/anticanres.14592

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To describe real clinical outcomes in patients with non-small cell lung cancer who have uncommon epidermal growth factor receptor (EGFR) mutations. Materials and Methods: We performed a retrospective chart review from 15 medical institutes that cover a population of three million people from April 2008 to March 2019. Results: There were 102 patients with uncommon EGFR mutation. Progression-free survival (PFS) tended to be longer in patients receiving afatinib compared with first-generation EGFR tyrosine kinase inhibitors. PFS in patients treated with afatinib or osimertinib was significantly longer than in patients treated with gefitinib or erlotinib (p=0.030). Multivariate analysis also revealed the contribution of afatinib or osimertinib to increased survival. In patients with exon 20 insertions, chemotherapy was efficacious. Conclusion: In treating patients with uncommon EGFR mutations, our results indicate longer-term survival might be achieved with second-generation or later TKIs and cytotoxic chemotherapeutic drugs.

引用

页码：5757 / 5764

页数：8

共 50 条

[1] Potential Usage of Afanitib in the Treatment of Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
Harada, Taishi
Yamaba, Yukiko
Hayata, Hiroki
Okuda, Takashi
Kimura, Yoshishige
Komaki, Toshiyuki
Kagawa, Keizo
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1241 - S1241
[2] EGFR mutations in non-small-cell lung cancer
Hung, Jung-Jyh
Jeng, Wen-Juei
Hsu, Wen-Hu
Liu, Jung-Sen
Wu, Yu-Chung
[J]. LANCET ONCOLOGY, 2010, 11 (05): : 412 - 413
[3] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
John, Thomas
Taylor, Aliki
Wang, Huifen
Eichinger, Christian
Freeman, Caroline
Ahn, Myung-Ju
[J]. CANCER EPIDEMIOLOGY, 2022, 76
[4] Effectiveness of icotinib against non-small-cell lung cancer with uncommon EGFR mutations.
Zhou, Shengyu
Hu, Xingsheng
Wang, Yan
Li Junling
Zhou, Liqiang
Hao, Xuezhi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, Luis
Soulieres, Denis
Melezinek, Ivan
Moecks, Joachim
Keil, Lorenz
Mok, Tony
Rosell, Rafael
Klughammer, Barbara
[J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (1-2) : 51 - 69
[6] Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
Jung, Hyun Ae
Park, Sehhoon
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
[J]. BIOLOGY-BASEL, 2020, 9 (10): : 1 - 10
[7] Prognosis of uncommon metastasis in non-small-cell lung cancer patients with mutated EGFR
Yoshimura, Akihiro
Tsuji, Taisuke
Takumi, Chieko
Hamashima, Ryosuke
Shiotsu, Shinsuke
Yuba, Tatsuya
Hiraoka, Noriya
[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[8] Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Moran, Teresa
Taus, Alvaro
Arriola, Edurne
Aguado, Carlos
Domine, Manuel
Gomez Rueda, Ana
Calles, Antonio
Cedres, Susana
Vinolas, Nuria
Isla, Dolores
Palmero, Ramon
Sereno, Maria
Diaz, Victor
Juan, Oscar
Marse, Raquel
Martin Martorell, Paloma
Sanchez Torres, Jose Miguel
[J]. CLINICAL LUNG CANCER, 2020, 21 (05) : 428 - +
[9] EGFR mutations in non-small-cell lung cancer reply
Mitsudomi, Tetsuya
Yatabe, Yasushi
[J]. LANCET ONCOLOGY, 2010, 11 (05): : 413 - 413
[10] First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
Kim, Mi-Hyun
Choi, Chang Min
Lee, Sung Yong
Park, Cheol Kyu
Chang, Yoon Soo
Lee, Kye Young
Kim, Seung Joon
Yang, Sei Hoon
Ryu, Jeong Seon
Lee, Jeong Eun
Lee, Shin Yup
Park, Chan Kwon
Lee, Sang Hoon
Jang, Seung Hun
Yoon, Seong Hoon
Jang, Tae Won
[J]. ANTICANCER RESEARCH, 2022, 42 (03) : 1615 - 1622

← 1 2 3 4 5 →